Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121888 · ClinicalTrials.gov registry record · Phase 1
Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy
A Phase 1 study of Stress Disorders, Post-Traumatic, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00121888 is a Phase 1 study of Stress Disorders, Post-Traumatic that has completed, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 155-participant average among 64 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00121888, a Phase 1 study of Stress Disorders, Post-Traumatic, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the effectiveness and tolerability of controlled-release paroxetine (Paxil-CR) compared to placebo (an inactive substance) for individuals who continue to have symptoms of post traumatic stress disorder (PTSD) despite receiving prolonged exposure therapy.
Conditions Studied
Interventions
- BEHAVIORAL Prolonged Exposure Therapy
- DRUG Paroxetine-CR
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121888
The ClinicalTrials.gov registry entry for NCT00121888 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 155-participant average among 64 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (61% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 2 interventions - of which Prolonged Exposure Therapy is the first listed.
NCT00121888 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00121888 about?
NCT00121888 is a clinical study titled "Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy". The purpose of the study is to evaluate the effectiveness and tolerability of controlled-release paroxetine (Paxil-CR) compared to placebo (an inactive substance) for individuals who continue to have symptoms of post traumatic stress disorder (PTSD) despite receiving prolonged exposure therapy.
What is the current status of trial NCT00121888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2002-12. Estimated completion is 2007-06.
What conditions does trial NCT00121888 study?
This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic.
What interventions are being tested in trial NCT00121888?
The interventions under investigation include: Prolonged Exposure Therapy (BEHAVIORAL), Paroxetine-CR (DRUG).
Who is sponsoring clinical trial NCT00121888?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00121888 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Disorders, Post-Traumatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Therapy for PTSD in Addiction Treatment
COMPLETED · Phase 1
-
Manage Emotions to Reduce Aggression (MERA)
RECRUITING · NA
-
SMART Therapist Training: A Hybrid Factorial-SMART Design
RECRUITING · NA
-
Overcontrol and Suicide in PTSD
RECRUITING
-
Postpartum Care in the NICU (PeliCaN) Transitions
RECRUITING · NA
-
Healthy Recovery After Trauma Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.